Posted inBiotechnology
GSK plans to lay off up to 350 R&D workers across US, UK
GSK is trimming its R&D team, a move expected to affect fewer than 50 workers in the U.K. and fewer…
Posted inBiotechnology
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't…
Posted inBiotechnology
How AI Is reshaping clinical trials and market access
Sponsored By H1 Feb 9, 2026 8:00am AI is no longer a future concept in life sciences — it is…
Posted inBiotechnology
Evaluating Wildlife Risks and Land Changes in Ethiopia
In the remote landscapes of North-eastern Ethiopia, a significant ecological evaluation has recently come to light, with potential far-reaching implications…
Posted inBiotechnology
Identifying GATA Transcription Factors in Cucurbitaceae Under Stress
In a groundbreaking study published in BMC Genomics, researchers led by Gao and his team have provided a comprehensive analysis…
Posted inBiotechnology
Integrated Acoustic Signatures Enhance Micro-Drone Detection
Recent advancements in technology have brought about significant innovations, particularly in the fields of artificial intelligence and machine learning. One…
Posted inBiotechnology
GSK gives back rights to Wave’s genetic disease RNA editor
Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. Partner GSK has…
Posted inBiotechnology
Peak Oxygen Consumption Modifies Obesity Paradox in Heart Failure
Obesity, a condition widely recognized for its detrimental effects on health, has long been associated with an increased risk of…
Posted inBiotechnology
Unlocking Tumor Lymph Node Metastasis with Single-Cell Omics
Recent advancements in cancer research are increasingly focusing on the multidimensional complexities associated with tumor metastasis, particularly within lymph nodes.…
Posted inBiotechnology
Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. Despite the success of Enhertu, the company has experienced two…